Literature DB >> 22160436

Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual.

Rachel A Davey1, Michele V Clarke, Stephen Sastra, Jarrod P Skinner, Cherie Chiang, Paul H Anderson, Jeffrey D Zajac.   

Abstract

Conditional gene inactivation using the Cre/loxP system has lead to significant advances in our understanding of the function of genes in a wide range of disciplines. It is becoming increasingly apparent in the literature, that Cre transgenic mice may themselves have a phenotype. In the following study we describe the bone phenotype of a commonly used Cre transgenic mouse line to study osteoblasts, the Osx-GFP::Cre (Osx-Cre) mice. Cortical and trabecular bone parameters were determined in the femurs of Osx-Cre mice at 6 and 12 weeks of age by microtomography (μCT). At 6 weeks of age, Osx-Cre mice had reduced body weight by 22% (P < 0.0001) and delayed cortical bone expansion and accrual, characterized by decreases in periosteal circumference by 7% (P < 0.05) and cortical thickness by 11% (P < 0.01), compared to wild type controls. Importantly, the cortical bone phenotype of the skeletally immature Osx-Cre mice at 6 weeks of age could be accounted for by their low body weight. The delayed weight gain and cortical growth of Osx-Cre mice was overcome by 12 weeks of age, with no differences observed between Osx-Cre and wild type controls. In conclusion, Osx-Cre expressing mice display a delayed growth phenotype in the absence of doxycycline treatment, evidenced by decreased cortical bone expansion and accrual at 6 weeks of age, as an indirect result of decreased body weight. While this delay in growth is overcome by adulthood at 12 weeks of age, caution together with appropriate data analysis must be considered when assessing the experimental data from skeletally immature Cre/loxP knockout mice generated using the Osx-Cre mouse line to avoid misinterpretation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160436     DOI: 10.1007/s11248-011-9581-z

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  28 in total

1.  Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors.

Authors:  Stephen J Rodda; Andrew P McMahon
Journal:  Development       Date:  2006-07-19       Impact factor: 6.868

2.  Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix.

Authors:  T A Owen; M Aronow; V Shalhoub; L M Barone; L Wilming; M S Tassinari; M B Kennedy; S Pockwinse; J B Lian; G S Stein
Journal:  J Cell Physiol       Date:  1990-06       Impact factor: 6.384

3.  Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model.

Authors:  A J Notini; R A Davey; J F McManus; K L Bate; J D Zajac
Journal:  J Mol Endocrinol       Date:  2005-12       Impact factor: 5.098

4.  Bone response to in vivo mechanical loading in two breeds of mice.

Authors:  M P Akhter; D M Cullen; E A Pedersen; D B Kimmel; R R Recker
Journal:  Calcif Tissue Int       Date:  1998-11       Impact factor: 4.333

5.  Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector.

Authors:  C A Strathdee; M R McLeod; J R Hall
Journal:  Gene       Date:  1999-03-18       Impact factor: 3.688

6.  The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice.

Authors:  Matthew B Greenblatt; Jae-Hyuck Shim; Weiguo Zou; Despina Sitara; Michelle Schweitzer; Dorothy Hu; Sutada Lotinun; Yasuyo Sano; Roland Baron; Jin Mo Park; Simon Arthur; Min Xie; Michael D Schneider; Bo Zhai; Steven Gygi; Roger Davis; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

7.  Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.

Authors:  A Kistner; M Gossen; F Zimmermann; J Jerecic; C Ullmer; H Lübbert; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage.

Authors:  Seth D Berman; Eliezer Calo; Allison S Landman; Paul S Danielian; Emily S Miller; Julie C West; Borel Djouedjong Fonhoue; Alicia Caron; Roderick Bronson; Mary L Bouxsein; Siddhartha Mukherjee; Jacqueline A Lees
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

9.  Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice.

Authors:  Rachel A Davey; Andrew G Turner; Julie F McManus; W S Maria Chiu; Francisca Tjahyono; Alison J Moore; Gerald J Atkins; Paul H Anderson; Cathy Ma; Vaida Glatt; Helen E MacLean; Cristina Vincent; Mary Bouxsein; Howard A Morris; David M Findlay; Jeffrey D Zajac
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

10.  Genetic variability in adult bone density among inbred strains of mice.

Authors:  W G Beamer; L R Donahue; C J Rosen; D J Baylink
Journal:  Bone       Date:  1996-05       Impact factor: 4.398

View more
  57 in total

1.  Multiple essential MT1-MMP functions in tooth root formation, dentinogenesis, and tooth eruption.

Authors:  H Xu; T N Snider; H F Wimer; S S Yamada; T Yang; K Holmbeck; B L Foster
Journal:  Matrix Biol       Date:  2016-01-15       Impact factor: 11.583

2.  Rothmund-Thomson Syndrome-like RECQL4 truncating mutations cause a haploinsufficient low bone mass phenotype in mice.

Authors:  Wilson Castillo-Tandazo; Ann E Frazier; Natalie A Sims; Monique F Smeets; Carl R Walkley
Journal:  Mol Cell Biol       Date:  2020-12-23       Impact factor: 4.272

3.  The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation.

Authors:  Jinhu Xiong; Maria Almeida; Charles A O'Brien
Journal:  Bone       Date:  2018-04-04       Impact factor: 4.398

4.  Tgfbr2 is required in osterix expressing cells for postnatal skeletal development.

Authors:  Sarah B Peters; Ying Wang; Rosa Serra
Journal:  Bone       Date:  2016-12-30       Impact factor: 4.398

5.  Role of SMPD3 during Bone Fracture Healing and Regulation of Its Expression.

Authors:  Garthiga Manickam; Pierre Moffatt; Monzur Murshed
Journal:  Mol Cell Biol       Date:  2019-02-04       Impact factor: 4.272

6.  Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes.

Authors:  Srividhya Iyer; Li Han; Elena Ambrogini; Maria Yavropoulou; John Fowlkes; Stavros C Manolagas; Maria Almeida
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

7.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

Authors:  Sutada Lotinun; Riku Kiviranta; Takuma Matsubara; Jorge A Alzate; Lynn Neff; Anja Lüth; Ilpo Koskivirta; Burkhard Kleuser; Jean Vacher; Eero Vuorio; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

8.  Autophagy Regulates Craniofacial Bone Acquisition.

Authors:  Neil Thomas; Han Kyoung Choi; Xiaoxi Wei; Li Wang; Yuji Mishina; Jun-Lin Guan; Fei Liu
Journal:  Calcif Tissue Int       Date:  2019-08-01       Impact factor: 4.333

9.  The glucocorticoid receptor in osteoprogenitors regulates bone mass and marrow fat.

Authors:  Jessica L Pierce; Ke-Hong Ding; Jianrui Xu; Anuj K Sharma; Kanglun Yu; Natalia Del Mazo Arbona; Zuleika Rodriguez-Santos; Paul Bernard; Wendy B Bollag; Maribeth H Johnson; Mark W Hamrick; Dana L Begun; Xing M Shi; Carlos M Isales; Meghan E McGee-Lawrence
Journal:  J Endocrinol       Date:  2019-07-01       Impact factor: 4.286

10.  Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual.

Authors:  Maria Almeida; Srividhya Iyer; Marta Martin-Millan; Shoshana M Bartell; Li Han; Elena Ambrogini; Melda Onal; Jinhu Xiong; Robert S Weinstein; Robert L Jilka; Charles A O'Brien; Stavros C Manolagas
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.